Bank of New York Mellon Corp Sells 1,238,206 Shares of Health Catalyst, Inc. (NASDAQ:HCAT)

Key Points

• The Bank of New York Mellon Corp significantly reduced its position in Health Catalyst, Inc. by 86.2% in Q1, selling over 1.2 million shares and holding 198,800 shares worth approximately $901,000.
• Health Catalyst has faced mixed analyst ratings, with five analysts rating it as a hold and seven assigning a buy rating, alongside a newly adjusted average price target of $8.00.
• The stock is currently trading around $3.52, with a 52-week range between $3.48 and $9.24, reflecting its volatility in the market.

Bank of New York Mellon Corp lowered its position in Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) by 86.2% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 198,800 shares of the company's stock after selling 1,238,206 shares during the quarter. Bank of New York Mellon Corp owned about 0.28% of Health Catalyst worth $901,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Group One Trading LLC boosted its holdings in shares of Health Catalyst by 107.6% in the fourth quarter. Group One Trading LLC now owns 4,360 shares of the company's stock valued at $31,000 after acquiring an additional 2,260 shares in the last quarter. Aquatic Capital Management LLC purchased a new stake in Health Catalyst in the 4th quarter worth approximately $63,000. Brevan Howard Capital Management LP purchased a new stake in Health Catalyst in the 4th quarter worth approximately $92,000. OneAscent Financial Services LLC purchased a new stake in Health Catalyst in the 4th quarter worth approximately $97,000. Finally, ExodusPoint Capital Management LP purchased a new stake in Health Catalyst in the 4th quarter worth approximately $107,000. Institutional investors and hedge funds own 85.00% of the company's stock.

Analysts Set New Price Targets

A number of research firms have issued reports on HCAT. Canaccord Genuity Group cut their target price on shares of Health Catalyst from $10.00 to $9.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. Evercore ISI cut their price target on shares of Health Catalyst from $5.00 to $4.00 and set an "in-line" rating on the stock in a report on Wednesday, July 9th. Stifel Nicolaus raised their price target on shares of Health Catalyst from $5.00 to $5.50 and gave the company a "hold" rating in a report on Thursday, May 8th. KeyCorp cut their price target on shares of Health Catalyst from $7.00 to $5.00 and set an "overweight" rating on the stock in a report on Wednesday, April 16th. Finally, BTIG Research downgraded shares of Health Catalyst from a "buy" rating to a "neutral" rating in a report on Tuesday, June 17th. Five research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $8.00.

Health Catalyst Price Performance

Shares of Health Catalyst stock traded down $0.01 during trading on Wednesday, hitting $3.81. 213,909 shares of the company's stock traded hands, compared to its average volume of 667,206. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.24 and a quick ratio of 1.24. The firm's fifty day moving average price is $3.86 and its 200 day moving average price is $4.30. Health Catalyst, Inc. has a twelve month low of $3.48 and a twelve month high of $9.24. The company has a market cap of $264.90 million, a PE ratio of -3.31 and a beta of 1.46.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.